These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 27622768)

  • 1. The RAD51C exonic splice-site mutations c.404G>C and c.404G>T are associated with familial breast and ovarian cancer.
    Neidhardt G; Becker A; Hauke J; Horváth J; Bogdanova Markov N; Heilmann-Heimbach S; Hellebrand H; Thiele H; Altmüller J; Nürnberg P; Meindl A; Rhiem K; Blümcke B; Wappenschmidt B; Schmutzler RK; Hahnen E
    Eur J Cancer Prev; 2017 Mar; 26(2):165-169. PubMed ID: 27622768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer.
    Weber-Lassalle N; Hauke J; Ramser J; Richters L; Groß E; Blümcke B; Gehrig A; Kahlert AK; Müller CR; Hackmann K; Honisch E; Weber-Lassalle K; Niederacher D; Borde J; Thiele H; Ernst C; Altmüller J; Neidhardt G; Nürnberg P; Klaschik K; Schroeder C; Platzer K; Volk AE; Wang-Gohrke S; Just W; Auber B; Kubisch C; Schmidt G; Horvath J; Wappenschmidt B; Engel C; Arnold N; Dworniczak B; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    Breast Cancer Res; 2018 Jan; 20(1):7. PubMed ID: 29368626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline RAD51C mutations in ovarian cancer susceptibility.
    Coulet F; Fajac A; Colas C; Eyries M; Dion-Minière A; Rouzier R; Uzan S; Lefranc JP; Carbonnel M; Cornelis F; Cortez A; Soubrier F
    Clin Genet; 2013 Apr; 83(4):332-6. PubMed ID: 22725699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants.
    Gutiérrez-Enríquez S; Bonache S; de Garibay GR; Osorio A; Santamariña M; Ramón y Cajal T; Esteban-Cardeñosa E; Tenés A; Yanowsky K; Barroso A; Montalban G; Blanco A; Cornet M; Gadea N; Infante M; Caldés T; Díaz-Rubio E; Balmaña J; Lasa A; Vega A; Benítez J; de la Hoya M; Diez O
    Int J Cancer; 2014 May; 134(9):2088-97. PubMed ID: 24130102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan.
    Rashid MU; Muhammad N; Faisal S; Amin A; Hamann U
    Breast Cancer Res Treat; 2014 Jun; 145(3):775-84. PubMed ID: 24800917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between Loss-of-Function Mutations Within the FANCM Gene and Early-Onset Familial Breast Cancer.
    Neidhardt G; Hauke J; Ramser J; Groß E; Gehrig A; Müller CR; Kahlert AK; Hackmann K; Honisch E; Niederacher D; Heilmann-Heimbach S; Franke A; Lieb W; Thiele H; Altmüller J; Nürnberg P; Klaschik K; Ernst C; Ditsch N; Jessen F; Ramirez A; Wappenschmidt B; Engel C; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    JAMA Oncol; 2017 Sep; 3(9):1245-1248. PubMed ID: 28033443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
    Janatova M; Soukupova J; Stribrna J; Kleiblova P; Vocka M; Boudova P; Kleibl Z; Pohlreich P
    PLoS One; 2015; 10(6):e0127711. PubMed ID: 26057125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAD51C mutation screening in high-risk patients from Serbian hereditary breast/ovarian cancer families.
    Krivokuca A; Yanowski K; Rakobradovic J; Benitez J; Brankovic-Magic M
    Cancer Biomark; 2015; 15(6):775-81. PubMed ID: 26406419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.
    Blanco A; Gutiérrez-Enríquez S; Santamariña M; Montalban G; Bonache S; Balmaña J; Carracedo A; Diez O; Vega A
    Breast Cancer Res Treat; 2014 Aug; 147(1):133-43. PubMed ID: 25086635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer.
    Zheng Y; Zhang J; Hope K; Niu Q; Huo D; Olopade OI
    Breast Cancer Res Treat; 2010 Dec; 124(3):857-61. PubMed ID: 20697805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
    Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
    Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer.
    Jønson L; Ahlborn LB; Steffensen AY; Djursby M; Ejlertsen B; Timshel S; Nielsen FC; Gerdes AM; Hansen TV
    Breast Cancer Res Treat; 2016 Jan; 155(2):215-22. PubMed ID: 26740214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families.
    Schnurbein G; Hauke J; Wappenschmidt B; Weber-Lassalle N; Engert S; Hellebrand H; Garbes L; Becker A; Neidhardt G; Rhiem K; Meindl A; Schmutzler RK; Hahnen E
    Breast Cancer Res; 2013 Dec; 15(6):R120. PubMed ID: 24359560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.
    Meindl A; Hellebrand H; Wiek C; Erven V; Wappenschmidt B; Niederacher D; Freund M; Lichtner P; Hartmann L; Schaal H; Ramser J; Honisch E; Kubisch C; Wichmann HE; Kast K; Deissler H; Engel C; Müller-Myhsok B; Neveling K; Kiechle M; Mathew CG; Schindler D; Schmutzler RK; Hanenberg H
    Nat Genet; 2010 May; 42(5):410-4. PubMed ID: 20400964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent moderate-risk mutations in Finnish breast and ovarian cancer patients.
    Nurmi A; Muranen TA; Pelttari LM; Kiiski JI; Heikkinen T; Lehto S; Kallioniemi A; Schleutker J; Bützow R; Blomqvist C; Aittomäki K; Nevanlinna H
    Int J Cancer; 2019 Nov; 145(10):2692-2700. PubMed ID: 30927251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline mutations in RAD51C in Jewish high cancer risk families.
    Kushnir A; Laitman Y; Shimon SP; Berger R; Friedman E
    Breast Cancer Res Treat; 2012 Dec; 136(3):869-74. PubMed ID: 23117857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility.
    Vuorela M; Pylkäs K; Hartikainen JM; Sundfeldt K; Lindblom A; von Wachenfeldt Wäppling A; Haanpää M; Puistola U; Rosengren A; Anttila M; Kosma VM; Mannermaa A; Winqvist R
    Breast Cancer Res Treat; 2011 Dec; 130(3):1003-10. PubMed ID: 21750962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
    Suszynska M; Klonowska K; Jasinska AJ; Kozlowski P
    Gynecol Oncol; 2019 May; 153(2):452-462. PubMed ID: 30733081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
    Chompret A
    J Gynecol Obstet Biol Reprod (Paris); 2003 Apr; 32(2):101-19. PubMed ID: 12717301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAD51C is a susceptibility gene for ovarian cancer.
    Pelttari LM; Heikkinen T; Thompson D; Kallioniemi A; Schleutker J; Holli K; Blomqvist C; Aittomäki K; Bützow R; Nevanlinna H
    Hum Mol Genet; 2011 Aug; 20(16):3278-88. PubMed ID: 21616938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.